Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495760 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL9011421 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL1115770 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL9497660 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL4072457 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL27759601 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL27458151 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL1537958 | 0.98 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL9499739 | 0.92 | CYP3A4 (0.54) | LPAR3LPAR2LPAR1CYP3A4P2RY10 | |
| SCHEMBL3463162 | 0.87 | LPAR3 (0.75) | LPAR3LPAR2LPAR1CYP3A4P2RY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240914-A | Deoxyribozyme and method for detecting mRNA capping rate | 南京鸿明生物科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118043078-A | SIRP-alpha antibodies and conjugates | 塔拉克治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117886982-A | Catalyst component and catalyst for olefin polymerization, and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117836413-A | Connexin-4 antibodies and conjugates | 塔拉克治疗公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117683769-A | Nucleic acid oligomer and use thereof | 瑞普鲁卡私人有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| CN-117440816-A | Modified MIR-135, conjugated forms thereof and uses thereof | 耶达研究及发展有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-109477111-B | Thermostable polymerase inhibitor compositions and methods | 塞弗德公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116887865-A | In vitro assembly of RNA-encapsulating finger ring viral capsids | 旗舰先锋创新V股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116829715-A | Compositions for treating CHD2 haploinsufficiency and methods of identifying same | 耶达研究及发展有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-101184840-A | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof | CALANDO PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | CN | disclosed |
| CN-1984921-A | Modulation of survivin expression | ISIS PHARMACEUTICALS INC (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1914335-A | Antisense oligonucleotide modulation of STAT3 expression | ISIS PHARMACEUTICALS INC (US) | 2007-02-14 | — | — | CN | disclosed |
| CN-1852979-A | Modulation of eIF4E expression | ISIS PHARMACEUTICALS INC (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1227035-C | Conjugates and method for production thereof, and their use for transporting molecules via biological membranes | AVENTIS PHARMA GMBH (DE) | 2005-11-16 | — | — | CN | disclosed |
| CN-1219551-C | Conjugates made of metal complexes and oligonucleotides | SCHERING AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| CN-1360507-A | Conjugates, methods for their preparation and use for transporting molecules across biological membranes | AVENTIS PHARMA GMBH (DE) | 2002-07-24 | — | — | CN | disclosed |
| US-5853986-A | Chemical promotion of nucleic acid hybridization | BECTON DICKINSON AND COMPANY (US) | 1998-12-29 | — | — | US | disclosed |
| CN-1152879-A | Conjugates made of metal complexes and oligonucleotides | SCHERING AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| CN-1083113-A | The rapid detection of biological polymer in the stained specimens | RES DEV FOUNDATION (US) | 1994-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | LPAR3 4532/4885LPAR2 4175/4885LPAR1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.